Chart, page-2299

I'd say the Google results are about as much as you could expect for a small biotech company with a generic name like "Antisense Therapeutics." Many of the results are about antisense therapy in general, rather than ANP. It's not something I'm too worried about at the moment. Once Phase IIB gets underway I'd imagine we'll get a lot more media coverage and therefore more Google hits.

I'm not sure what ANP's US-based Investor Relations Director Erin Cox is doing to earn her pay. Doesn't seem like much. She joined ANP in 2018 according to her LinkedIn. She had previously worked for Sarepta under Goolsbee. Perhaps Goolsbee brought her along? I wouldn't mind bringing on some heavier hitters in the US.

While ANP seems to be taking a very staid, conservative approach to stock promotion, which may pay off in the long run in terms of company credibility, it can be maddening as a shareholder.